Market Research Logo

Global Hepatitis Drugs Market 2015-2019

Global Hepatitis Drugs Market 2015-2019

About hepatitis

Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.

Technavio's analysts forecast the global hepatitis drugs market to grow at a CAGR of 17.1% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global hepatitis drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hepatitis.

Technavio's report, Global Hepatitis Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the segmentation. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA
Key vendors
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Vertex Pharmaceuticals
Other prominent vendors
  • Abbvie
  • Achillion Pharmaceuticals
  • Bristol-Myers Squibb
  • Dynavax Technologies
  • Mitsubishi Tanabe Pharma
Key market driver
  • Emergence of IFN-free therapies
  • For a full, detailed list, view our report
Key market challenge
  • Side-effects of current therapy
  • For a full, detailed list, view our report
Key market trend
  • Collaborations and M&A
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Hepatitis Drugs Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Hepatitis Drugs Market: F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis and Vertex Pharmaceuticals
Other Prominent Vendors in the market are: Abbvie, Achillion Pharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies and Mitsubishi Tanabe Pharma
Commenting on the report, an analyst from Technavio’s team said: “The global hepatitis drugs market in emerging countries such as India, Brazil, China, and Russia is expected to grow at a rapid pace during the forecast period owing to an increase in patient population and public awareness about hepatitis. Drug manufacturers focus on these countries with the motive of launching new products and penetrating these markets.”
According to the report, early detection of hepatitis is important in reducing the chances of developing liver infections, which can prevent extensive liver damage. Various government and non-government organizations organize awareness campaigns and other programs to educate people about the disease and therapeutic measures available.
Further, the report states that the patent expiration of approved drugs is expected to have an adverse impact on the market, slowing down market growth during the forecast period.

Companies Mentioned

F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Vertex Pharmaceuticals, Abbvie, Achillion Pharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Mitsubishi Tanabe Pharma

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Disease overview
    • Understanding the disease
    • Classification
    • Mode of transmission
      • Table Mode of transmission and incubation period of different types of hepatitis
      • Table Risk factors for hepatitis A transmission
      • Table Risk factors for hepatitis B transmission
      • Table Risk factors for hepatitis C transmission
    • Epidemiology
      • Table Worldwide endemicity of HAV infection
      • Table Endemicity pattern of HBV worldwide
      • Table Prevalence of HBV in APAC
      • Table Acute hepatitis B infection by age group 2005-2013
      • Table Prevalence of hepatitis B in US 2005-2013
      • Table Estimated HBV incidence rates in APAC countries 2004
      • Table Prevalence rates of hepatitis C across different regions 2012
    • Diagnosis
      • Table Antibodies indicating different hepatitis types
      • Table Tests for viral proteins and generic materials
      • Table Screening tests for hepatitis B infection
      • Table Screening tests for hepatitis C infection
    • Symptoms
      • Table Types of hepatitis and symptoms
    • Treatment
      • Table Recommended dosages and schedules for hepatitis A vaccines
      • Table Recommended dosages and schedules for hepatitis B vaccines
      • Table Combination vaccines for hepatitis A and/or hepatitis B
  • Key marketed drugs
    • Hepatitis A
      • Table Hepatitis A: Key marketed vaccines
    • Hepatitis B
      • Table Hepatitis B: Key marketed drugs
    • Hepatitis C
      • Table Hepatitis C: Key marketed drugs
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global hepatitis drugs market 2014-2019 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type
    • Table Market segmentation by type
    • Hepatitis A
      • Table Global hepatitis A drugs market 2014-2019 ($ billions)
    • Hepatitis B
      • Table Global hepatitis B drugs market 2014-2019 ($ billions)
    • Hepatitis C
      • Table Global hepatitis C drugs market 2014-2019 ($ billions)
      • Table Snapshot of global hepatitis drugs market
  • Market segmentation by MOA
    • Table Classification of global hepatitis drugs market by MOA
    • Virus-specific agents
    • Non-specific agents
  • Geographical segmentation
    • Table Global hepatitis drugs market by geographical segmentation 2014
  • Market drivers
    • Table List of key drivers
  • Impact of drivers
  • Market challenges
    • Table List of key challenges
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table List of key trends
  • Vendor landscape
    • Competitive scenario
    • Gilead Sciences
      • Table Gilead: Pipeline candidates for hepatitis B
      • Table Gilead Sciences: Pipeline candidates for hepatitis C
      • Table Gilead Sciences: Key takeaways
    • Johnson & Johnson
      • Table Johnson & Johnson: Global YoY revenue of Incivo 2012-2014 ($ millions)
      • Table Johnson & Johnson: Global revenue of Olysio 2014 ($ millions)
      • Table Johnson & Johnson: Key takeaways
    • F. Hoffman-La Roche
      • Table Roche: Pipeline candidates for hepatitis C
      • Table F. Hoffman-La Roche: Key takeaways
    • Merck
      • Table Merck: Global YoY revenue of Victrelis 2011-2013 ($ millions)
      • Table Merck: Pipeline candidates for hepatitis C
      • Table Merck: Key takeaways
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Pipeline candidates for hepatitis B
      • Table GlaxoSmithKline: Pipeline candidates for hepatitis C
      • Table GlaxoSmithKline: Key takeaways
    • Vertex Pharmaceuticals
      • Table Vertex Pharmaceuticals: Global YoY revenue of Incivek 2011-2013 ($ millions)
      • Table Vertex Pharmaceuticals: Pipeline candidates for hepatitis C
      • Table Vertex Pharmaceuticals: Key takeaways
    • Novartis
      • Table Novartis: Key takeaways
    • Other prominent vendors
  • Key vendor analysis
    • Gilead Sciences
      • Table Gilead Sciences: List of key drugs
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Segmentation by product 2014
      • Table GlaxoSmithKline: Geographical segmentation by revenue 2014
      • Table GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
    • Johnson & Johnson
      • Table Johnson & Johnson: Business segmentation
      • Table Johnson & Johnson: Key products of medical devices segment
      • Table Johnson & Johnson: Medical devices segmentation by revenue 2014
    • Merck
      • Table Merck: Business segmentation
      • Table Merck: Geographical segmentation
      • Table Business segmentation by revenue
    • Novartis
      • Table Novartis: Business segmentation
      • Table Novartis: Geographical segmentation
      • Table Novartis: Business segmentation by revenue
    • Roche
      • Table Roche: Business segments
      • Table Roche: Pharmaceuticals segmentation
      • Table Roche: Revenue comparison by business segment
      • Table Roche: Geographical segmentation
    • Vertex Pharmaceuticals
      • Table Vertex Pharmaceuticals: Product segmentation by revenue
      • Table Vertex Pharmaceuticals: Product segmentation by revenue 2013 and 2014 ($ millions)
      • Table Vertex Pharmaceuticals: Geographical segmentation
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report